Investor Alert

Jan. 17, 2021, 12:06 a.m. EST

Paraganglioma Market to Demonstrate Progress at a ~6.1% of CAGR by 2023

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

Jan 17, 2021 (Heraldkeepers) -- MarketResearchFuture.com adds "Paraganglioma Market -2017 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023" reports to its database.

The report titled "Paraganglioma Market -Forecast to 2023" is a direct appreciation by Market Research Future of the market potential of the Paraganglioma Market. The report intends to provide accurate and meaningful insights, both quantitative as well as qualitative. It can be said with high confidence level, that this report will satisfy the need for comprehensive insights needed to compete and beat other players in today's winner takes all market! The global paraganglioma market is expected to grow at a CAGR of 6.1% during the forecast period 2017-2023.

Regional Analysis of Global Paraganglioma Market:

The Americas dominate the global market owing to a huge population suffering from paraganglioma, strong government support for research & development and high health care spending. According to the Centers for Disease Control and Prevention, in 2014, over 14.1 million of new cancer cases were registered worldwide. Increasing prevalence of the disease has boosted the market growth in America. Additionally, changing lifestyle and smoking further fuel the growth of the market.

Europe accounts for the second leading market in the global paraganglioma market, which is followed by Asia Pacific. Asia Pacific is the fastest growing paraganglioma market. It is majorly driven by India, China and Japan owing to a huge number of patients and rapidly growing economy. Governments in Asia Pacific region are supporting manufacturers for research & development, which can serve as a path for the development of the market. The Middle East and Africa contribute the least to the growth of the global market. The Middle East dominates the market of the Middle East and African region owing to the presence of the UAE, Saudi Arabia, and Kuwait. Africa holds the least share of the global market due to limited availability of medical facilities and poor economic condition of the region. However, the growth of the African market is high due to the presence of opportunities for the development of the market.

Key Players for Paraganglioma Market:

Some of key the players in the market are Bristol-Myers Squibb Company (U.S.), GlaxoSmithKline Plc. (U.K.), Bayer AG (Germany), Novartis AG (Switzerland), Spectrum Pharmaceuticals Inc. (U.S.), Amgen, Inc. (U.S.), Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Janssen Biotech, Inc. (U.S.), AbbVie Inc. (U.S.), Takeda Pharmaceuticals (Japan), Pfizer, Inc. (U.S.), Sanofi (France), Merck & Co., Inc. (U.S.), Immunomedics (U.S.), and Oncomed Pharmaceuticals (U.S.).

Market Scenario of theParaganglioma Market:

Paragangliomas, also called glomus tumors, is a rare and slow-growing tumor arising from non-chromaffin paraganglion cells, which are distributed throughout the body from the base of the skull to the urinary bladder. However, in over 50% cases it occurs in the temporal bone. The global paraganglioma market is expecting a healthy growth in the coming future. The global market is majorly driven by increasing paraganglioma patients across the globe. Additionally, increasing smoking population and rising consumption of alcohol have spurred the growth of the market. However, side effects of the treatment, long time for approval, and high cost may slow the growth of the market over the review period.

GET SAMPLE REPORT @ https://www.marketresearchfuture.com/sample_request/4838 .

Segmentation of Global Paraganglioma Market:

The global paraganglioma market is segmented on the basis of types, treatment, and end users.

On the basis of types, the market is segmented into caroid paraganglioma, cervical paraganglioma, jugular paraganglioma, secretory paraganglioma, temporal paraganglioma, vagal paraganglioma, and others.

On the basis of the treatment, the market is categorized into therapeutic treatment and diagnostic treatment. The therapeutic treatment is further segmented into surgery, embolization, and radiotherapy. The embolization is further categorized into liquid embolic agents, sclerosing agents, particulate embolic agents, and others. The radiotherapy is sub-segmented into external beam radiation therapy, brachytherapy, and unsealed source radiotherapy. The diagnostic treatment is further segmented into CT scans, MRI, angiography, blood test, and others.

On the basis of the end users, the market is segmented into hospital & clinics, ambulatory care centers, and others.

Major TOC of Paraganglioma Market:

Chapter 1 Report Prologue

Chapter 2 Market Introduction

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.